Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 9, Issue 2, 2015, Pages 88-95

  Vidal, Carol ^a   Reese, Carla ^a   Fischer, Bernard A ^a,b   Chiapelli, Joshua ^a   Himelhoch, Seth ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Meta analysis; Mirtazapine; Negative symptoms; Schizophrenia

Indexed keywords

HALOPERIDOL; MIRTAZAPINE; PLACEBO; MIANSERIN; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; OUTCOME ASSESSMENT; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MIANSERIN; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84936945435     PISSN: 19351232     EISSN: 19412010     Source Type: Journal    
DOI: 10.3371/CSRP.VIRE.030813     Document Type: Review

References (32)

1. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32(2):214-219.
2. Strauss GP, Harrow M, Grossman LS, Rosen C. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr Bull 2010;36(4):788-799.
3. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994;151(3):351-356.
4. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88(1-3):5-25.
5. Zoccali R, Muscatello MR, Bruno A, Cambria R, Mico U, Spina E, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007;93(1-3);109-116.
6. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64(5):361-368.
7. Siris SG, Mason SE, Bermanzohn PC, Alvir JM, McCorry TA. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol Bull 1990;26(1):91-94.
8. Rao ML, Moller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology 1994;30(4):160-172.
9. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000;15(5):257-261.
10. Silver H, Nassar A, Aharon N, Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 2003;18(2):87-92.
11. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9(4):281-285.
12. Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18(5):399-403.
13. Hayashi T, Yokota N, Takahashi T, Tawara Y, Nishikawa T, Yano T, et al. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1997;12(4):199-205.
14. Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, et al. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int Clin Psychopharmacol 2002;17(2):59-64.
15. Sepehry AA, Potvin S, Elie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68(4):604-610.
16. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chornic schizophrenia: meta-analysis. Br J Psychiatry 2010;197(3):174-179.
17. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71-93.
18. Phan SV, Kreys TJ. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy 2011;31(10):1017-1030.
19. Terevnikov V, Stenberf JH, Joffe M, Tiihonen J, Burkin M, Tchoukhine E, et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Human Psychopharmacol 2010;25(6):431-438.
20. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):1080-1086.
21. Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004;19(2):71-76.
22. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol 2010;13(4):433-441.
23. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(1):208-211.
24. Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 2010;116(2-3):101-106.
25. Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 2009;24(3):233-238.
26. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 2009;108(1-3):245-251.
27. Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16(2):87-92.
28. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157(6):987-993.
29. Fischer BA, Kirkpatrick B, Carpenter WT. The neurobiology of negative symptoms and the deficit syndrome. In: Javitt DC, Kantrowitz JT, editors. The handbook of neurochemistry and molecular neurobiology: schizophrenia. 3rd ed. New York: Springer Science and Business Media LLC; 2009. p. 507-523.
30. Morita M, Nakayama K. Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. Psychiatry Clin Neurosci 2011;65(3):246-253.
31. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 1998;44(11):1099-1117.
32. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989;46(8):745-753.